Sysmex (6869) Investor update summary

Review of the previous mid-term management plan

• Hematology achieved targets due to global expansion and strong growth in emerging markets like India and Brazil.

• Hemostasis and medical robot businesses missed targets due to regulatory delays, market changes, and hospital management issues.

• China underperformed due to healthcare cost control policies, impacting overall sales and profitability.

• Despite high growth in hematology and emerging markets, overall targets for profit growth and ROE were missed.

Strategic priorities and themes

• Focus on diagnostics business, launching new products, and leveraging digital transformation (DX).

• Improve profitability through value chain transformation and cost-competitive structure.

• Advance medical DX, data utilization, and automation to enhance operational efficiency.

• Strengthen supply chain resilience and stakeholder accountability.

Growth strategies and market initiatives

• Launch flagship and next-generation diagnostic models globally, with AI integration to boost competitiveness.

• Accelerate growth in hemostasis in Europe and the Americas, and achieve double-digit growth in emerging markets.

• In China, adapt to cost controls by localizing production and optimizing business structure.

• Expand medical robotics, neurology, and regenerative medicine businesses as new growth drivers.